# OnCo record parabilis-medicines (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/parabilis-medicines/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "parabilis-medicines" ;
  schema:name "Parabilis Medicines"@en ;
  schema:alternateName "FogPharma"@en, "FOG Pharmaceuticals"@en ;
  schema:description "Parabilis Medicines makes stabilised peptides, small protein fragments locked into a helix so they can enter cells and grip cancer proteins that ordinary pills cannot. Its lead medicine, zolucatetide, blocks the beta-catenin signal behind desmoid tumours, and a phase 3 trial is planned for 2027."@en ;
  schema:url <https://onco.cc/companies/parabilis-medicines/>, <https://parabilismed.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://parabilismed.com/>, <https://investors.parabilismed.com/>, <https://www.sec.gov/Archives/edgar/data/1657677/000119312526265983/pbls_424b4.htm>, <https://www.sec.gov/Archives/edgar/data/1657677/000119312526262880/ck0001657677-20260609.htm>, <https://investors.parabilismed.com/news-releases/news-release-details/parabilis-medicines-reports-second-quarter-2026-financial> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/desmoid-tumour/>, <https://onco.cc/cancers/fap-associated-colorectal-cancer/>, <https://onco.cc/cancers/hcc/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/prostate/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/protac-degrader/> ;
  onco:targets <https://onco.cc/targets/ctnnb1/>, <https://onco.cc/targets/erg/>, <https://onco.cc/targets/androgen-receptor/> .